Smith and Nephew, the global medical technology business, and the University of Hull are working on a long-term collaboration project to drive research into pioneering approaches to advanced wound care.
Together, we’re creating one of the world’s largest Wound Care Research Clusters, combining world-leading academia and industry. The aim is to develop scientific insights and innovative treatments for advanced wound care.
Over the next five years, and with a co-investment of around £3 million, this exciting partnership will deliver significant patient benefits, and create eight multi-disciplinary PhD studentships.
The collaboration has been welcomed by new local MP Emma Hardy.
“Britain is a global leader in medical technology innovation. Partnerships such as this between Smith & Nephew and the University of Hull further strengthen our position at the forefront of global medical research and development. Creating one of the largest wound care clusters in the world is a huge vote of confidence in the UK as a whole and Hull in particular, as we build a ‘global Britain’ with pioneering medical technology at its heart.”
Supporting the collaboration is Smith & Nephew’s new state-of-the-art Research & Development (R&D) centre in Hull, and the University’s £28-million new Health Campus. Smith & Nephew’s R&D hub for wound management technologies, specialises in toxicology, chemistry and microbiology among other specialist fields.
Stewart McKinlay, Vice President of Research & Innovation, Smith & Nephew, said
“We are thrilled that the University of Hull shares our passion for the importance of advancing the science of wound care. Pioneering innovation is a strategic priority for Smith & Nephew. This partnership will combine the brightest minds with the finest R&D facilities available with the aim of better supporting healthcare professionals in the advanced treatment of wounds, which is an area of significant unmet medical need and a substantial cost to healthcare systems.
“There will be opportunities for students and employees to interact on a daily basis, to share knowledge, best practice, and support our ambitious R&D pipeline. Combine that with the scale of scientific specialities that is based here, then this partnership is a truly exciting prospect.”